Dehydration

This research evaluates how well furosemide alone compares to furosemide combined with albumin in critically ill adults who have fluid overload. The study aims to find out if adding albumin improves urine output and kidney function markers compared to using furosemide by itself. Key measurements include urine output two hours after treatment, kidney blood flow indicators, and various biochemical tests. Participants are randomly assigned to receive either furosemide at 1 mg per kg of body weight intravenously over 30 minutes with a placebo, or the same dose of furosemide together with 50 grams of 25% albumin infused over 30 minutes. The study uses bedside ultrasound to assess fluid overload signs and monitors blood pressure, electrolytes, and kidney filtration rates during the trial. During the study, participants undergo urine output measurement at two hours and blood tests to track changes in kidney function and electrolyte levels up to 24 hours after treatment. Ultrasound evaluations assess vein size and congestion at baseline and after two hours. Researchers monitor safety and response to treatment while collecting data on urine volume and kidney health markers to understand the impact of adding albumin to furosemide therapy.

Researchers are evaluating the safety and effectiveness of VBI-S in raising blood pressure in patients suffering from septic shock with absolute or relative hypovolemia. Septic shock is a severe condition caused by infection leading to dangerously low blood pressure that does not improve with standard fluid treatments. This study is a Phase III, open-label, randomized controlled trial sponsored by Vivacelle Bio, aiming to address this urgent medical emergency. Participants will receive treatment with VBI-S, which consists of small particles of specific lipids called micelles and liposomes designed to treat hypotension. The study is randomized and controlled but open-label, meaning both participants and researchers know the treatment given. The Data Safety Monitoring Board will regularly review safety and study data to ensure participant well-being. During the study, participants will be closely monitored through various assessments including measurements of mean arterial pressure, doses of pressor drugs, organ function scores, oxygen levels, serum markers, and survival rates over a 12-month period. The primary outcome is the elevation in average mean arterial pressure. Assessments will help determine how VBI-S affects blood pressure and organ function while ensuring ongoing safety throughout the study duration.

Researchers are evaluating the safety, side effects, and effectiveness of brenipatide LY3537031 in adults with Irritable Bowel Syndrome-Diarrhea IBS-D. The study compares brenipatide administered under the skin with a placebo to understand its impact on this condition. This Phase 2 clinical trial involves participants aged 18 to 75 years. Participants will receive either the study drug brenipatide or a placebo through subcutaneous injections. The study follows a randomized, double-blind design where neither participants nor researchers know which treatment is given. Treatment and placebo administrations occur during the trial, which lasts approximately 35 weeks. During the study, participants will be monitored for how well they tolerate the drug and any side effects. Researchers will collect daily data on abdominal pain and stool consistency using an eDiary, focusing on responses between weeks 9 and 24. The primary measure is the percentage of participants achieving a daily composite response for at least half the days between weeks 9 and 16. Safety and efficacy outcomes are tracked throughout the trial period.

Researchers are evaluating the safety and preliminary effectiveness of SER-155, an experimental live bacterial therapeutic, as a first treatment for people experiencing diarrhea related to immunotherapy-induced enterocolitis irEC. This study focuses on adults with grade 2-3 diarrhea due to irEC who have not received immunosuppressive therapy before. The trial aims to find out if SER-155 causes few or mild side effects while addressing these symptoms. Participants will receive SER-155 orally, which consists of 16 unique human-commensal bacterial strains encapsulated for ingestion. The study is single-arm and open-label, meaning all participants will receive this experimental treatment without a comparison group. The treatment and observation will last up to one year, with assessments at various time points including days 15 and 43. During the study, participants will be monitored for treatment-related side effects and clinical responses to irEC without immunosuppressive drugs. Researchers will collect data on adverse events, treatment response and remission rates, and bacterial strain detection in the participants. The study involves regular assessments over a year to carefully track safety and treatment outcomes.

Researchers are evaluating the safety and efficacy of centhaquine citrate LYFAQUIN173, a new drug for treating hypovolemic shock, a serious condition caused by severe blood or fluid loss. This phase IV, prospective, multi-center, open-label study builds on previous findings that centhaquine can improve blood pressure, reduce blood lactate levels, increase cardiac output, and reduce death rates by acting on specific adrenergic receptors to improve blood flow. Participants with hypovolemic shock aged 18 years or older and a systolic blood pressure of 90 mmHg or lower at hospital admission will receive centhaquine in addition to standard shock care. Centhaquine is given intravenously at a dose of 0.01 mgkg body weight over one hour in saline. A second dose may be given if blood pressure remains low, with a maximum of three doses in 24 hours, and treatment can continue for up to two days after enrollment. During hospitalization, participants will be closely monitored and followed until discharge or seven days after enrollment. Researchers will measure safety by tracking adverse events and serious adverse events up to seven days. They will also assess blood pressure, blood lactate, base deficit, time in intensive care, ventilator use, urine output, mortality rates, and organ function scores. Statistical analyses will compare patient outcomes to evaluate centhaquines effects.

This trial is focused on adults with cancer who are receiving chemotherapy and experience nausea and vomiting as side effects. Researchers are studying a drug called LY3537021 to see how well it controls these symptoms and to evaluate its safety. The study is a Phase 2, double-blind, placebo-controlled trial designed to better understand the treatment options for chemotherapy-induced nausea and vomiting in this population. Participants are randomly assigned to receive either LY3537021 or a placebo, both given as a subcutaneous injection before chemotherapy. All participants also receive standard anti-nausea treatments, which may be taken orally, intravenously, or through skin patches. The chemotherapy drugs involved include cisplatin or an anthracycline and cyclophosphamide combination. The study treatment is given prior to chemotherapy, and the trial lasts about two months per participant. During the study, participants will be monitored for nausea and vomiting from the time of their chemotherapy infusion through up to five days afterward. Researchers will collect data on symptom control, the need for rescue medications, and drug levels in the body. Participants will complete diaries to track nausea severity. Safety and response to treatment are carefully observed. The study aims to measure how many participants have a complete response to nausea and vomiting during the delayed phase after chemotherapy.

Bone tumor surgery often leads to significant blood loss, which can cause postoperative anemia and increase the risk of complications and affect long-term survival. Researchers are evaluating the effect of acute normovolemic hemodilution ANH combined with goal-directed fluid therapy GDFT in patients undergoing bone tumor surgery. This study aims to determine if ANH can improve hemoglobin levels after surgery, addressing previous uncertainties about ANHs clinical benefits when fluid management is carefully controlled. Participants are randomly assigned to one of two groups. In the ANH group, blood is drawn after anesthesia and replaced with a fluid to maintain blood volume, followed by GDFT during surgery. In the standard care group, only GDFT is applied throughout the surgery without ANH. The trial carefully monitors fluid management strategies to assess the impact of ANH on patient outcomes. Throughout the study, participants will have their hemoglobin levels measured on the first day after surgery as the primary outcome. Secondary measures include blood loss, blood transfusion rates, fluid volume during surgery, coagulation tests, and infections up to seven days post-surgery. The study includes preoperative assessments, intraoperative monitoring, and postoperative follow-up to evaluate safety and efficacy over the hospital stay period.

Cardiovascular diseases are a leading cause of death worldwide, with increasing concerns about metabolic dysfunction and type 2 diabetes. Research suggests that the hormone arginine vasopressin AVP, which regulates body fluid balance, may be linked to diabetes risk when water intake is low. This study aims to explore whether increasing water intake with plain water or non-sugar-sweetened beverages can improve hydration, glucose regulation, and cardiovascular health in normal-weight and obese adults. The study involves two groups of adults classified by body mass index BMI as normal weight or obese. Participants will follow an 8-week crossover design with periods of habitual fluid intake, low, moderate, and adequate fluid intake using either plain water or non-sugar-sweetened beverages. Fluid intake is controlled by providing drinks and smart water bottles that record intake and send reminders. The study includes a washout period and weekly lab visits for assessments. Participants will attend weekly lab visits after fasting for at least 10 hours. Assessments include hydration biomarkers from urine samples, body composition, blood pressure, cognitive tests, resting metabolic rate, endothelial function via ultrasound, and oral glucose tolerance tests with multiple blood draws. Continuous glucose monitoring will occur throughout the intervention. Mood, sleep quality, diet, and physical activity will also be monitored using questionnaires and wearable devices. The studys main outcomes include measures of vascular function and glucose regulation over the 8 weeks.

This research aims to evaluate whether a thirst kit using a lemon popsicle can reduce thirst intensity in adults undergoing hospital bowel preparation for colonoscopy. The study also examines if the kit can lessen symptoms like dry mouth and dry throat and how satisfied patients are with this intervention compared to a placebo. The trial is designed to randomly assign participants to either the thirst kit or a placebo group for comparison. Participants will receive either a lemon-flavored popsicle with an encouraging message or a placebo consisting of distilled water in a blister pack with a cotton ball and the same message. These interventions are used during the hospital bowel preparation period before colonoscopy. The lemon popsicle group receives a 60g popsicle from a specific brand, while the placebo group receives a 10 ml water blister pack. During the study, participants will rate their thirst intensity and related symptoms using numerical scales just before sedation begins for the colonoscopy. Researchers will collect these ratings to assess the primary outcome of thirst intensity. The entire process occurs in the hospital setting, and the study includes adults aged 18 and older who are undergoing bowel preparation for colonoscopy. The studys main measurement happens 10 minutes before sedation when patients arrive at the examination room.

The trial investigates how the drugs propranolol and metoprolol affect core body temperature in older adults during extreme heat exposure. It aims to understand why adults over 65 have higher rates of heat-related illness and death, especially since beta blockers are commonly prescribed for cardiovascular conditions in this age group. This is important because previous studies in younger people showed beta blockers affect sweating and blood flow, but their impact on older adults in heat is unknown. Participants will experience 3 hours of heat exposure in a chamber set to 41C with 40% humidity. They will receive different sequences of propranolol, metoprolol, and placebo in a randomized, double-blind manner to compare effects on their body temperature and sweat rate. The study involves multiple treatment arms rotating these drugs to assess their influence during simulated heat waves. During the study, researchers will continuously measure internal body temperature, heart rate, and blood pressure while also tracking whole body sweat rate before and after heat exposure by measuring body mass. The trial focuses on healthy adults aged 65 and older who meet specific health criteria. The total observation lasts through the 3-hour heat exposure, with close monitoring of cardiovascular and thermoregulatory responses to understand drug effects in aging individuals.